Sunovion Pharmaceuticals and Otsuka Pharmaceutical Development & Commercialization (Otsuka) have announced the randomisation of the first patient in a Phase II/III clinical trial of ulotaront to treat generalised anxiety disorder (GAD).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,